- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02321072
Optimal Oxygenation in the Intensive Care Unit (O2-ICU)
The Effects of Hyperoxia on Organ Dysfunction and Outcome in Critically Ill Patients With SIRS
Objectives:
- To study the short- and long-term effect of two different PaO2 targets on circulatory status, organ dysfunction and outcome in patient admitted to the ICU with Systemic Inflammatory Response Syndrome (SIRS) criteria.
- To study underlying mechanisms of hyperoxia by determining differences in oxidative stress response between the hyperoxic and the normoxic patients.
Study design:
Randomized, prospective multicentre clinical trial
Study population:
Patients admitted to the Intensive Care unit with ≥ 2 positive SIRS-criteria and an expected ICU stay of more than 48 hours
Intervention:
Group 1: target PaO2 120 (105 - 135) mmHg (high-normal)
Group 2: target PaO2 75 (60 - 90) mmHg (low-normal)
Primary endpoints:
The primary endpoint will be cumulative daily delta SOFA score (CDDS) from day 1 to day 14.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale:
Contrary to hypoxia, many physicians do not consider hyperoxia harmful for their patients. To prevent hypoxia, superfluous administration of oxygen is common practice, and hyperoxia is seen in many patients, especially on Intensive Care units. However, an increasing number of studies not only confirm the known negative pulmonary effects of chronic oxygen oversupply, but also important and more acute circulatory effects, characterised by decreased cardiac output (CO), increased systemic vascular resistance (SVR), and impaired microvascular perfusion. These phenomena can impair perfusion of organs, which may outweigh higher arterial oxygen content, resulting in a net loss of oxygen delivery and perturbed organ function. This may for example be responsible for hyperoxia-associated increased infarct size and increased mortality after myocardial infarction and cardiac arrest. The underlying mechanisms are not clarified yet, but probably involve increased oxidative stress with systemic vasoconstriction.
On the other hand, hyperoxia can also induce several favourable effects. The majority of ICU-patients have a systemic inflammatory response syndrome (SIRS) with concomitant vasoplegia due to trauma, sepsis or ischemia/reperfusion injury. Vasoconstriction could benefit these patients with severe SIRS, reducing the need for intravenous volume resuscitation and vasopressor requirements. Furthermore, hyperoxia may exert a preconditioning effect in patients with ischemia/reperfusion injury and prevent new infections due to its antibacterial properties.
Hypothesis:
Hyperoxia during SIRS ultimately has unfavourable effects on organ function, especially on a longer term.
Objectives:
- To study the short- and long-term effect of two different PaO2 targets on circulatory status, organ dysfunction and outcome.
- To study underlying mechanisms of hyperoxia by determining differences in oxidative stress response between the hyperoxic and the normoxic patients.
Study design:
Randomized, prospective multicentre clinical trial
Study population:
Patients admitted to the Intensive Care unit with ≥ 2 positive SIRS-criteria and an expected ICU stay of more than 48 hours
Intervention:
We will investigate 2 groups with PaO2 targets both within the range of current practice
Group 1: target PaO2 120 (105 - 135) mmHg (high-normal)
Group 2: target PaO2 75 (60 - 90) mmHg (low-normal)
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands, 1081 HV
- VU University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
≥2 positive SIRS-criteria:
- Temperature >38 deg.C or hypothermia <36 deg.C
- Heart rate >90 bpm
- Respiratory rate >20 /min or pCO2 <32 mmHg (4.3 kPa)
- Number of leucocytes >12 x 10^9/l of <4 x 10^9/l of >10% bands
- Within 12 hours of admittance to the ICU
- Expected stay of more than 48 hours as estimated by the attending physician
Exclusion Criteria:
- Elective surgery
- Carbon monoxide poisoning
- Cyanide intoxication
- Methemoglobinemia
- Sickle cell anemia
- Severe pulmonary arterial hypertension (WHO class III or IV)
- Known severe Acute Respiratory Distress Syndrome (ARDS) (PaO2/FiO2 ≤100 mmHg and PEEP ≥ 5 cm H2O)
- Known cardiac right to left shunting
- Pregnancy
- Severe Chronic Obstructive Pulmonary Disease (COPD) (Gold class III or IV) or other severe chronic pulmonary disease
- Patients participating in other interventional trials
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: High-normal PaO2
In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a PaO2 of 120 mmHg (16 kPa), range 105-135 mmHg (14-18 kPa).
|
|
Active Comparator: Low-normal PaO2
In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a target PaO2 of 75 mmHg (10 kPa), range 60-90 mmHg (8-18 kPa).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily Delta Sequential Organ Failure Assessment Score
Time Frame: 14 days
|
The primary endpoint will be cumulative daily delta SOFA score (CDDS) from day 1 to day 14, calculated as the sum of [daily SOFA score minus admission SOFA score] from day 2 to day 14. Daily SOFA score is calculated as the total of maximum scores for each organ system excluding respiratory system (because of possible PaO2/FiO2 distortion). For patients discharged from the ICU, SOFA score will be registered as 0 from the day of discharge to day 14. Death in the ICU will be registered as a score of 20 (maximum) from the day of death to day 14. |
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
total maximum SOFA score minus SOFA score on admission
Time Frame: 14 days
|
14 days
|
|
SOFA rate of decline
Time Frame: 14 days
|
14 days
|
|
Total maximum SOFA score, total maximum SOFA score minus SOFA score on admission, SOFA rate of decline
Time Frame: 14 days
|
14 days
|
|
Mortality
Time Frame: 14 days, in-ICU (max 90 days), in-hospital (max 90 days)
|
14 days, in-ICU (max 90 days), in-hospital (max 90 days)
|
|
Hypoxic events (PaO2 <55 mmHg)
Time Frame: 14 days
|
14 days
|
|
Vasopressor / Inotrope requirements
Time Frame: 14 days
|
14 days
|
|
Renal function, fluid balance
Time Frame: 14 days
|
14 days
|
|
Oxidative stress (F2-isoprostanes)
Time Frame: days 1, 3, 7
|
days 1, 3, 7
|
|
Duration of mechanical ventilation and ventilator-free days
Time Frame: 14 days
|
14 days
|
|
Length of stay (ICU)
Time Frame: average expected 2 to 28 days
|
average expected 2 to 28 days
|
|
Length of stay (hospital)
Time Frame: average expected 10 to 28 days
|
average expected 10 to 28 days
|
|
Systemic Vascular Resistance Index
Time Frame: 14 days
|
In a random subpopulation.
|
14 days
|
Cardiac Index
Time Frame: 14 days
|
In a random subpopulation.
|
14 days
|
Microcirculatory flow index and Perfused vessel density
Time Frame: 14 days
|
In a random subpopulation.
Composite endpoint for two sidestream dark-field microcirculatory measurements.
|
14 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: A.M.E. de Man, MD, PhD, Amsterdam UMC, location VUmc
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014/459
- 2014-003468-19 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Inflammatory Response Syndrome
-
University of CologneCompletedSystemic Inflammatory Response Syndrome (SIRS)Germany
-
Arkansas Children's Hospital Research InstituteEunice Kennedy Shriver National Institute of Child Health and Human Development...TerminatedSIRS (Systemic Inflammatory Response Syndrome(United States
-
Medical University of GdanskCompletedInflammatory Response Syndrome, Systemic | Granulocyte Immature FormsPoland
-
ImmunexpressJohns Hopkins University; Northwell Health; Rush University Medical Center; Intermountain... and other collaboratorsCompletedSepsis | Systemic Inflammatory Response Syndrome (SIRS)United States
-
Chinese PLA General HospitalCompletedSepsis | SIRS(Systemic Inflammatory Response Syndrome)China
-
Chinese PLA General HospitalUnknownSepsis | SIRS(Systemic Inflammatory Response Syndrome)China
-
Seattle Children's HospitalImmunexpressCompletedSepsis | Systemic Inflammatory Response Syndrome (SIRS)United States
-
University of ArkansasTerminatedPediatric Patients With SIRS (Systemic Inflammatory Response Syndrome)United States
-
University Hospital, LimogesTerminatedSevere Sepsis | Inflammatory Response Syndrome, SystemicFrance
-
Seattle Children's HospitalImmunexpressCompletedSepsis | Non-Infectious Systemic Inflammatory Response SyndromeUnited States
Clinical Trials on Oxygen
-
National Baromedical ServicesMayo Clinic; Dartmouth-Hitchcock Medical Center; Eastern Virginia Medical School and other collaboratorsCompletedCarcinoma, Squamous Cell | Cancer of the Head and NeckUnited States
-
Aalborg University HospitalRigshospitalet, Denmark; Copenhagen Trial Unit, Center for Clinical Intervention...Active, not recruitingHypoxemic Respiratory Failure | Oxygen ToxicityNorway, Switzerland, Denmark
-
Aalborg University HospitalUniversity of AarhusUnknownCardiac Surgery | Cardiopulmonary Bypass | Acute Lung Injury | Hyperoxia | Oxygen ToxicityDenmark
-
Chang, Steve S., M.D.Santa Barbara Cottage HospitalCompletedPostoperative AbscessUnited States
-
Princess Margaret Hospital for ChildrenCompleted
-
Royal Brompton & Harefield NHS Foundation TrustLiverpool University Hospitals NHS Foundation Trust; National Institute for...CompletedLung; Disease, Fibroid (Chronic)United Kingdom
-
UMC UtrechtThe Netherlands Cancer InstituteCompletedBreast Cancer | Radiation ToxicityNetherlands
-
Ain Shams UniversityRecruitingOxygen Therapy | Pulmonary ResectionEgypt
-
Heidelberg UniversityRecruitingPulmonary Arterial Hypertension | Oxygen Deficiency | CTEPHGermany
-
Aalborg University HospitalRigshospitalet, Denmark; Copenhagen Trial Unit, Center for Clinical Intervention...CompletedHypoxemic Respiratory Failure | Oxygen ToxicityUnited Kingdom, Denmark, Finland, Iceland, Netherlands, Norway, Switzerland